BRD5529
BRD5529 is an effective dose-dependent CARD9-TRIM62 protein–protein interaction (PPI) inhibitor with an IC50 value of 8.6 μM. BRD5529 has potency and complete inhibition of CARD9 ubiquitinylation in vitro, also has favorable solubility. BRD5529 can be used for the research of inflammatory bowel disease (IBD) such as Crohn’s disease (CD) and ulcerative colitis (UC) [1][2].
Product Specifications
CAS Number
1358488-78-4
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
E1/E2/E3 Enzyme
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Infection; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/brd5529.html
Purity
98.94
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(C1=CC(NC(C2=CC=C(C)C=C2)=O)=CN=C1N3CCC(N4CCCCC4)(C(N)=O)CC3)O
Molecular Formula
C25H31N5O4
Molecular Weight
465.54
Precautions
H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
IL-4 / Interleukin 4 (IL4/1597), CF488A conjugate, 0.1mg/mL
P27 / KIP1 (SX53G8), CF488A conjugate, 0.1mg/mL
